Curis vs Immunome
CRIS and IMNM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and IMNM compare
Immunome is the larger company, worth 1777 times as much as Curis ($2.1B against $1.2M).
Curis grew revenue faster over the last twelve months (−62.2% versus −63.3% for Immunome).
Curis keeps more of each dollar of sales as profit, with a net margin of −490% compared with −5594% at Immunome.
Curis scores higher on the StockData Score (7 against 6 for Immunome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | IMNM |
|---|---|---|
| Size and price | ||
| Market cap | $1.2M | $2.1B |
| Share price | $0.572 | $18.70 |
| Change, 1 year | −97.7% | 6.7% |
| Change, 5 years | −100.0% | 8.7% |
| Beta (5Y) | 1.90 | 1.73 |
| Employees | 24 | 177 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 529× |
| P/B | 0.3× (better) | 4.7× |
| FCF yield | – | −9.7% |
| Fair value | $6.71 | – |
| Margin of safety | 91.5% | – |
| Growth | ||
| Revenue growth (TTM) | −62.2% (better) | −63.3% |
| Revenue growth, 5Y average | −2.7% | – |
| Profitability | ||
| Operating margin | −203% (better) | −5948% |
| Net margin | −490% (better) | −5594% |
| FCF margin | – | −5119% |
| Return on equity | – | −62.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.49 | 11.66 (better) |
| Altman Z-score | −96.16 | 21.76 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −2057% | – |
| Shareholder yield | −2057% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 32.1% | 104% |
| Held by insiders | 20.4% | 6.4% |
| Insider net buying, 12 months | $5.5K (better) | −$25.2M |
| Short interest, % of float | 61.8% | 15.2% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- IMNM stock overview
- IMNM income statement
- IMNM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.